Goldman Ismail Secures Victory in First Paragard IUD Bellwether Trial

On February 4, 2026, Goldman Ismail secured a complete defense verdict for Teva Pharmaceuticals in the first Paragard copper IUD bellwether trial in the Northern District of Georgia.

The plaintiff accused Teva of failure to warn, defective design, fraud, and negligent misrepresentation of breakage risks after her Paragard contraceptive device broke during removal. The jury found in favor of Teva on all counts, after deliberating for about four hours.

Partners Shayna Cook and Rami Fakhouri served as lead trial counsel and handled key witness throughout. Shayna delivered the opening and closing arguments, explaining that breakage is a known and rare risk of all intrauterine devices and that, despite that risk, Paragard is still widely considered safe and effective by doctors.  

Following the verdict, a Teva spokesperson told Reuters “we will continue to vigorously defend against claims that we believe misrepresent this important product’s safety profile.”

Goldman Ismail’s trial team included associates Bridget Wholey and Nia Vogel and was also supported by Chris Morris, Pamela Ferrell, Kyle Cummins, and Jordan Walker at Butler Snow, Teva’s national counsel.